Europe seeks common ground on AI in drug regulation

AI is becoming increasingly important in pharmaceutical research, clinical development and medicines safety monitoring. European regulators now face a fundamental question: how can they support innovation while ensuring that AI-generated evidence remains scientifically reliable and medicines continue to meet established safety and efficacy standards?

That challenge was the main focus to a meeting between European medicines regulators and pharmaceutical industry representatives on 5 October 2026. The European Medicines Agency (EMA) published the meeting agenda and summary notes on 14 October, providing further insight into the regulatory dialogue surrounding AI.

The discussions form part of the joint 2025–2028 workplan of the EMA and the Heads of Medicines Agencies (HMA). Rather than introducing new binding requirements, the initiative provides a forum for addressing emerging technologies, regulatory expectations and the practical challenges of using AI throughout the medicines lifecycle.

Regulatory evidence

AI is already being explored for identifying drug candidates, analysing biological data, supporting clinical trial design and monitoring medicine safety. However, an algorithm that performs well in a research environment does not automatically produce evidence suitable for regulatory decision-making. Regulators must be able to assess whether AI models are reliable, whether their underlying data are representative and whether their outputs remain valid when applied to different populations or settings.

The October meeting included a discussion on how medicines regulation can contribute to enabling AI innovation in Europe. Industry representatives were invited to present their perspectives on the opportunities and regulatory challenges associated with emerging technologies. The distinction between encouraging innovation and accepting regulatory evidence is particularly important.

AI may accelerate certain stages of drug development, but faster analysis does not necessarily mean that medicines can be approved more quickly. Developers must still demonstrate quality, safety and efficacy through appropriate scientific evidence. For regulators, the challenge is therefore not simply whether AI should be permitted, but how its use can be evaluated consistently and proportionately.

Interoperability and cooperation

Data interoperability was another major topic on the agenda. Pharmaceutical research increasingly relies on information originating from different organisations, databases and healthcare systems. AI applications may combine clinical trial data, laboratory results, medical images and real-world health information. Differences in data formats, terminology and quality can limit the usefulness of these datasets. Interoperability is consequently more than a technical issue. It also affects whether AI-generated findings can be reproduced, compared and independently assessed. The meeting also addressed international regulatory cooperation.

Pharmaceutical development is inherently international, while AI technologies frequently operate across national and organisational boundaries. Diverging regulatory expectations could complicate the development and evaluation of AI-based methods. Closer cooperation between regulatory authorities may help establish more consistent principles for model validation, documentation and responsible use.

Nevertheless, international alignment does not eliminate differences between legal systems. European requirements concerning data protection, medicines regulation and artificial intelligence must still be considered when AI applications are developed or deployed.

Guidance for clinical development

One of the most significant subjects discussed was the development of regulatory guidance for AI in clinical drug development. The meeting brought together industry perspectives and updates from the European regulatory network. Participants were also scheduled to receive information about the AI Guidance Coordination Group. This reflects a broader shift in European medicines regulation.

AI is no longer being considered exclusively as an emerging research technology. Regulators increasingly need to determine how AI-supported methods fit into established processes for developing, evaluating and monitoring medicines. Clinical development presents particular challenges. AI can potentially support patient selection, trial design, data analysis and the identification of treatment-related risks.

However, the regulatory implications depend on how a model is used. An algorithm supporting an exploratory research analysis raises different questions from one that directly influences patient eligibility, clinical endpoints or conclusions about treatment effectiveness. The level of scrutiny must therefore reflect the intended use of the technology and the consequences of incorrect results.

The EMA and HMA have already established a dedicated industry dialogue to examine such questions. The group was created under the Network Data Steering Group workplan and is intended to meet several times annually. Its purpose is to exchange information and identify regulatory needs, rather than assess individual medicines or make product-specific decisions.

Balancing innovation and patient safety

The discussions illustrate the growing importance of AI governance within pharmaceutical regulation. For industry, greater clarity about regulatory expectations can support investment and development. For authorities, early engagement offers opportunities to understand emerging applications before they become established practice. Patients ultimately have a different interest: confidence that medicines developed or evaluated using AI meet the same scientific standards as other treatments. That requires more than technically sophisticated algorithms. Data quality, transparency, validation, accountability and appropriate human oversight remain essential.

The European regulatory network is continuing this dialogue through its 2025–2028 programme, with further stakeholder discussions planned. The central challenge is becoming increasingly clear. Europe needs regulatory approaches that can accommodate rapidly evolving AI technologies without weakening the evidence required to protect patients.

The meeting represents another step in that process, although dialogue and guidance development should not be confused with completed regulatory reforms. The practical impact will depend on the standards eventually adopted and how consistently they are applied throughout pharmaceutical development and safety monitoring.